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Abstract: Ascorbic acid (vitamin C, AA) has long been considered a food supplement necessary for life and for preventing scurvy. How-
ever, it has been reported that other small molecules such as retinoic acid (vitamin A) and different forms of calciferol (vitamin D) are di-
rectly involved in regulating the expression of numerous genes. These molecules bind to receptors that are differentially expressed in the 
embryo and are therefore crucial signalling molecules in vertebrate development. The question is: is ascorbic acid also a signalling mole-
cule that regulates gene expression?  
We therefore present and discuss recent publications that demonstrate that AA regulates the expression of a battery of genes. We offer a 
clue to understanding the biochemical mechanism by which AA regulates gene expression. Finally we will discuss the question of a re-
ceptor for AA and its potential involvement in embryonic development and cell differentiation. 
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INTRODUCTION 
  In humans, L-Ascorbic acid (vitamin C) is essential for life 
(which is why it is called a vitamin) by virtue of its antioxidant 
properties, which protect cells against oxidative stress [1]. Vitamin 
C deficiency is termed scurvy [2]. James Lind, in 1747, was the 
first to conclude that eating fruits could prevent scurvy. During the 
18
th and 19
th centuries, foods able to prevent scurvy were termed 
antiscorbutic, although the chemical principle was not identified. 
Albert Szent-Gyorgyi’s group first isolated the antiscorbutic princi-
ple and named it ascorbic acid (he received the Nobel Prize in 
1937).  
  Ascorbic acid (AA) is a sugar acid with the same furanose ring 
as ribose. Most animals and plants synthesize AA from glucose 
through a four-enzyme pathway [3-5]. However, primates (as well 
as guinea pigs) have lost the ability to synthesize ascorbic acid be-
cause they lack one enzyme, L-gulonolactone oxidase, in the bio-
synthetic process [6,7]. Therefore, normal primate diets should 
include foods containing ascorbic acid (fruits, sauerkraut, ...).  
  Ascorbic acid is liberated in the digestive tract by digestion and 
transported into the blood by SVCT1 (SLC23A1) [8-10], a glyco-
protein located on the apical and basal faces of the epithelial cells 
[11]. SVCT1 is also located in the kidney [12,13], where it partici-
pates in reabsorption into the circulation. 
  SVCT2 (SLC23A2) is a membrane protein located at the apical 
poles of polarized cells [14]. It transports AA into cells via a Na-
dependent mechanism, which allows the intracellular AA concen-
tration to exceed the extracellular concentration. AA binding to 
SVCT2 is very specific, as most closely-related analogues are not 
properly transported by it [15]. The intracellular distribution of AA 
and exact biological role of SVCT2 have not been fully elucidated.  
  The metabolic and biochemical properties of AA have been 
extensively documented. Most of them are associated with the 
chemical nature of the molecule, indicating its antioxidant proper-
ties. Surprisingly, until recently, AA was not considered a potential 
signalling molecule as (e.g.) vitamins A and D are. We will discuss 
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this new hypothesis and its significance for gene expression in the 
following pages and document it by reference to recent publica-
tions. 
ASCORBIC ACID AND GENE EXPRESSION 
  As mentioned above, AA has long been considered either as an 
enzymatic co-factor or as a molecule that acts through the antioxi-
dant properties attributable to its chemical structure. The first indi-
cation that it might also modulate gene expression was documented 
in a series of articles describing the stimulation of procollagen 
mRNA by ascorbate [16-18]. The authors clearly demonstrated that 
this effect was at the transcriptional level. Two other recent papers 
reported the action of AA on expression of the gene encoding a new 
form of collagen involved in extracellular matrix formation [19,20]. 
However, no clear explanation has been proposed, except for indi-
rect effects such as hydroxyproline oxidation [21]. 
  Therefore, although AA has been shown to regulate the expres-
sion of genes encoding extracellular matrix proteins, no additional 
gene or gene family was proposed until recently. In 2004, Passage 
et al. [22], demonstrated that treatment of a mouse model of the 
Charcot-Marie-Tooth 1A disease reverts, at least partly, to the 
transgenic mouse phenotype. This disease is due to the overexpres-
sion of a major myelin gene, PMP22, and AA treatment lowers 
PMP22 expression. In the same year, using microarrays represent-
ing about 6000 genes, Shin et al. published a series of genes re-
sponding to AA treatment of embryonic stem cells [23]. Most of the 
overexpressed genes belonged to gene families involved in neuro-
genesis, maturation and neurotransmission. More recently, Park et 
al. published a proteomic analysis of cancer cells treated with AA 
[24]. The most relevant effects seem to be overexpression of RKIP 
and Annexin A5. Finally, in February this year, Belin et al. pub-
lished an article describing changes of gene expression in normal 
and cancer cells treated with increasing doses of AA [25]. They 
used pangenomic arrays. The most striking result was that only 30 
genes were down-regulated by AA treatment. Among these, 12 
belonged to two families, tRNA synthetases and translation initia-
tion factors, involved in cell division. The authors demonstrated 
that AA stops cell proliferation in vivo and in vitro, and kills the 
dividing cells by necrosis at higher concentration. 
  To our knowledge, only one mechanism by which AA could 
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of the intracellular cAMP pool; we will discuss this later. Are genes 
expressed and regulated through the cAMP-dependent pathway the 
only ones affected by AA treatment? That remains an open ques-
tion. 
  A general question regarding the control of gene expression by 
small molecules concerns a potential receptor. Receptors for Vit A 
and Vit D have been well described and characterized (see below), 
but no classical receptor has been described for AA so far. How-
ever, two proteins with high affinity for AA have been described, 
SVCT1 and SVCT2 (for review see [26]). Both are AA transporters 
and act through a Na-dependent mechanism. SVCT1 is located in 
the intestine and kidney and is involved in AA transport into the 
blood. In contrast, SVCT2 is present in the plasma membranes of 
different cell types. It has a very specific affinity for L-ascorbic 
acid and does not recognize closely-related molecules [15]. It en-
ables AA to accumulate inside cells, though we do not know ex-
actly where the intracellular AA is located.  
  Interestingly, the gene encoding a key enzyme in AA biosyn-
thesis, L-gulono-gamma-lactone synthase, accumulates mutations 
in man and guinea pig [27, 28]. In consequence, these two species 
cannot synthesis AA. In contrast, SVCT2 is one of the most evolu-
tionarily conserved molecules and no species lacks this key protein. 
We may conclude that it is not AA biosynthesis itself, but the ac-
cumulation of AA in cells mediated by SVCT2, that is most impor-
tant for organisms. The involvement of SVCT2 in AA signal recep-
tion will thus be very interesting to investigate. 
GENE EXPRESSION AND BIOLOGICAL/BIOCHEMICAL 
FUNCTIONS OF ASCORBIC ACID 
  What could be the mechanism by which AA acts on gene ex-
pression?  
  The first clearly established function of AA was to prevent 
scurvy. Evidence that AA was necessary to prevent the appearance 
of this fatal disease was described above, with no indication of 
other roles this molecule might play. 
  From its chemical structure, AA is an electron donor and there-
fore a reducing agent. It thus has two different biochemical roles: as 
an antioxidant and as an enzymatic cofactor. It is an electron donor 
for different enzymes, including three involved in collagen hy-
droxylation [21, 29], two in carnitine synthesis [30,31], and others 
in norepinephrin [32] and tyrosine [33] synthesis. AA deficiency is 
therefore associated with extracellular matrix defects that are 
probably implicated in the vascular problems observed in scurvy. 
  This enzymatic property certainly has an impact on cell me-
tabolism that could influence gene expression. However, these 
mechanisms are probably not directly involved in the control of 
gene expression and cell signalling. The first explanation came 
from recent results obtained by our group. As we described above, 
AA treatment lowers the expression of PMP22, which is overex-
pressed in CMT1A patients [34]. This is probably the basis of the 
phenotypic correction observed in a CMT animal model. Expres-
sion of PMP22 is under the control of cAMP, via fixation of CREB 
on a site located on the promoter (1.5 kb from the transcription 
initiation site) [34-37]. Incubation of Schwann cell lines with in-
creasing concentrations of AA results in dosage-dependent inhibi-
tion of PMP22 expression. In addition, the intracellular cAMP pool 
is decreased when cells are incubated with increasing AA concen-
trations [34]. This inhibition is specific to AA and does not occur 
with other antioxidants
  [38]. Recently, using classical enzymatic 
experiments, it has been demonstrated that AA is a competitive 
inhibitor of adenylate cyclase
 [39], probably because AA and ATP 
both have a furanose ribose ring (with different side chains). There-
fore, AA could repress the expression of genes under the control of 
the cAMP-dependent pathway. 
  What could be the effect of this new property on biological 
phenomena? Two lines of research indicate that AA may be in-
volved in cell differentiation. The first regards Schwann cell differ-
entiation and myelination. It has been demonstrated that AA is 
needed in Schwann cell/axon co-cultures to induce myelin forma-
tion [40-42]. However, no clear mechanism has been demonstrated 
other than antioxidant properties. The second line of research has 
been initiated more recently and involves embryonic stem cell (ES) 
differentiation. Using high throughput screening of a chemical li-
brary, Takahashi et al. found that AA was the only molecule pre-
sent in the library that promoted differentiation of murine ES in 
cardiomyocytes [43]. They also demonstrated that this effect is 
specific to AA and is not shared with other antioxidants, so antioxi-
dant mechanisms are probably not involved in this process.  
 Finally,  Sotiriou  et al. described the phenotype of a mouse mu-
tant in which the gene encoding SVCT2 was inactive [44]. In ho-
mozygotes, the AA concentration in the extracellular fluid was 
normal but the molecule could not enter cells. Embryos died in the 
perinatal period with anomalies in the lungs and blood vessels.  
  These different observations clearly raise questions about AA 
as a signalling molecule in mammalian development and differen-
tiation. These are fascinating new topics that will probably develop 
in the near future. 
OTHER VITAMINS AND GENE EXPRESSION 
  As already mentioned, several "vitamins" have been shown to 
play roles in the regulation of gene expression. We will focus on the 
two best-documented molecules: Vitamin A and Vitamin D.  
Vitamin A 
  Vitamin A and its bioactive metabolites have pleiotropic effects 
in all tissues involving cellular development, proliferation, differen-
tiation, metabolism and apoptosis. 
  About 50% of the vitamin A intake is derived from animal 
products that contain retinol and retinyl esters; the remaining 50% 
is provided by plant carotenoids. The active form of vitamin A is 
retinoic acid (RA). The amount of vitamin A needed by an adult is 
5-600 mg per day, and any prolonged deficit or excess in this daily 
intake causes serious heath problems. Vitamin A deficiency (VAD) 
is deleterious to embryo formation (reviewed in [45]) and is respon-
sible for a large array of congenital malformations affecting the 
ocular, cardiac, respiratory and urogenital systems. Conversely, 
retinoids administered in excess to pregnant females typically in-
duce truncation of the anterior brain (an- or ex-encephaly) and pos-
teriorization of hindbrain rhombomeres. So, in embryos, vitamin A 
excess or deficit leads to severe anomalies of development. The 
function of RA signalling in development has been extensively 
studied using transgenic mice [46]. The main conclusion is that 
signalling through RARs is indispensable for embryonic patterning 
and organogenesis, and the RA signalling pathway plays a crucial 
role in development. The level of RA is critical. In adults, VAD is 
associated with xerophthalmia (irreversible degradation of the cor-
nea) leading in the worst case to blindness. The critical role of vi-
tamin A in maintaining the immune response to infectious diseases 
is well documented. Characteristic adverse effects of hypervitami-
nosis A are alopecia, elevation of serum triglycerides, hyperostosis, 
and extraskeletal calcification. 
  The widespread nature of retionoid bioactivities is due, in large 
part, to their ability to regulate the expression of target genes. All-
trans and 9-cis retinoic acid, the retinoids active in regulating gene 
expression in cell nuclei, are ligands that bind and activate cognate 
retinoid receptors. These receptors, in turn, function as transcription 
factors that regulate the expression of target genes. 
  In the nucleus there are two distinct classes of retinoid recep-
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(RXR), and the nonsteroid, thyroid/retinoid/vitamin D superfamily 
of nuclear receptors (NRs). These are Class II NRs, which het-
erodimerize with RXR and bind to direct repeat (DR) elements in 
the target genes [47]. 
  The classical retinoid response element of a target gene is a DR 
of the motif 5V-PuG(G/T)TCA-3V spaced by 1, 2 or 5 base pairs 
(DR1, DR2 and DR5, respectively) [48-50]). It has been established 
that RARs are ligand-dependent transcription factors, and repress 
transcription in the absence of ligand.  
  Transcriptional activation by NRs entails a complex mechanism 
(for review see [51]). Briefly, the first step is the binding of the 
ligand to RAR or RXR, leading to conformational changes in the 
NRs. The second critical step is DNA binding. The third is the re-
cruitment of coactivators or the release of corepressors (numerous 
functional groups of coactivators and corepressors have been char-
acterized). The last step leads to a modified chromatin structure and 
finally to an increased transcription initiation rate.  
 Beside  activation  via NRs, RA signalling could lead to transrep-
ression, responsive to repression of transcription factors such as 
AP1 and NF-kB.  
  The mechanisms of gene regulation by RA have been reviewed 
using PEPCK as a model gene; it exemplifies the pleiotropic effects 
of retinoids [52].  
  A listing and categorization of retinoid-responsive genes cited 
532 RA-target genes. This review distinguished genes subject to 
direct, classic retinoid signalling from those subject to indirect RA 
regulation [53]. Category 3 included 27 genes unquestionably   
controlled through the classical RA pathway in some cellular   
context(s): ADH1C, CD38, CDX1, CEBPE, CRABP2, CRYAB B, 
DRD2, EGR1, ETS1, FOXA1, H1F0, HOXA1, HOXA4, HOXB1, 
HOXB4, HOXD4, HSD17B1, IL2RA, PCK1, PIT1, RARA, RARB, 
RARG, RBP1, SFTPB, TGM2, UCP1. Category 2 included 105 
genes that may be modulated at the transcriptional level, but other 
indicators of direct regulation have not yet been explored. In most 
cases, there is still a lack of data relating to response elements or 
RAR.RXR involvement. Category 1 included 267 genes. RA regu-
lates them in some way; there are insufficient data to distinguish 
between direct or indirect regulation. Category 0 included 124 
genes that seem to be regulated indirectly in the contexts studied.  
  These vast arrays of genes regulated by RA signalling, and the 
developmental effects of RA signalling, make this small molecule 
more than a vitamin but a real morphogen. 
Vitamin D 
  Vitamin D (vitD) is a key vitamin in the control of calcium 
level, which is the most tightly-regulated plasma ion level. VitD 
coordinates the participation of four different tissues in calcium 
homeostasis - kidney, intestine, bone and parathyroid - so it is 
clearly a hormone more than a vitamin. It is essential for the devel-
opment and maintenance of a mineralized skeleton by controlling 
bone formation and also the absorption of calcium and phosphate, 
two keys components of bone, by the intestine. It is not only in-
volved in the regulation of calcium homeostasis and bone minerali-
zation via vitamin D receptor (VDR) activation but also has anti-
proliferative, pro-differentiation, and immunomodulatory activities. 
The vitD endocrine system also participates in the regulation of 
blood pressure, volume homeostasis, cardiac function, and protec-
tion of renal cellular integrity. 
  Humans obtain vitamin D from exposure to sunlight, from their 
diet, and from dietary supplements. A diet high in oily fish prevents 
vitD deficiency. Solar ultraviolet B radiation (wavelength 290-315 
nm) penetrates the skin and induces the photolytic conversion of 7-
dehydrocholesterol to previtamin D3, followed by thermal isomeri-
zation to vitamin D3. The first step in the metabolic activation of 
vitD is hydroxylation of carbon 25, which occurs primarily in the 
liver and is catalyzed by 25-hydroxylase. 25-OH-D3 is the metabo-
lite measured to evaluate vitamin D deficiency. The second step in 
vitD bioactivation is the formation of 1,25-dihydroxyvitamin D3 
[1,25-(OH)2D] from 25-hydroxyvitamin D3. This occurs under 
physiological conditions, mainly in the kidney. Renal 1-
hydroxylase activity is highly regulated, in keeping with the potent 
activity of its product in calcium homeostasis. Dietary calcium 
regulates the enzyme, directly through changes in serum calcium, 
and indirectly by altering parathyroid hormone (PTH) levels [53].  
  VitD deficiency (VDD) is associated with rickets in children 
and osteomalacia in adults [54]. Besides this well-described bone 
effect, VDD is suspected of being associated with numerous dis-
eases: muscle weakness and falling, cancer, cardiovascular diseases 
and autoimmune diseases (see review in [55]). 
  Excess vitD is associated with hypercalcemia and hypercalci-
uria and can lead to serious complications. It may be secondary to 
excessive ingestion of vitamin or to excessive and unregulated pro-
duction of 1,25-OH2-D3, by granulomata in sarcoidosis or tubercu-
losis for example. 
  The clinical effects of deficiency or excess in vitD are directly 
linked to the regulation of gene expression by active vitD metabo-
lites via nuclear receptors. 1,25(OH)2D3 regulates gene expression 
in target cells by binding to the vitamin D receptor (VDR). The 
liganded VDR heterodimerizes with the retinoid X receptor (RXR), 
binds to vitamin D response elements (VDREs) in the promoters of 
target genes and, together with coactivators or corepressors, affects 
target gene transcription. Directly or indirectly, 1,25-OH2 D 3 con-
trols between 200 and 500 of the 20,488 genes in the human ge-
nome, including genes responsible for regulating cellular prolifera-
tion, differentiation, apoptosis, and angiogenesis. 
  Most of the biological activities of 1,25(OH)2D3 require a 
high-affinity receptor, the VDR, an ancient member of the NR II 
superfamily. Like the other members of the steroid receptor family, 
the VDR acts as a ligand-activated transcription factor. 
  We may summarize five major steps in the control of gene tran-
scription by the VDR:  
-  Ligand binding (in the cytoplasm). In the absence of ligand, 
most of the VDR is present in the cytoplasm. Ligand bind-
ing induces conformational changes, enhancing dimeriza-
tion with RXR.  
-  Heterodimerization with the retinoid X receptor (RXR). 
RXR, a nuclear receptor for 9-cis retinoic acid, is an obliga-
tory partner of VDR in mediating 1,25-(OH)2D3 action. 
-  Translocation of the heterodimer VDR-RXR with ligand 
from the cytoplasm to the nucleus. 
-  Binding of the heterodimer to vitD response elements 
(VDREs) in the promoters of 1,25(OH)2D-responsive 
genes. Canonical VDREs are direct repeats of 5-
AGG/TTCA-3, or a minor variation of this motif, separated 
by three nucleotides and commonly referred to as DR-3 mo-
tifs. 
-  Recruitment of VDR-interacting nuclear proteins (coregula-
tors) into the transcriptional preinitiation complex, which 
markedly enhance or suppress the rate of gene transcription 
by the VDR. Ligand binding in general increases the affin-
ity of the VDR for various protein cofactors that act as a 
bridge between the RXR-VDR heterodimer and the basal 
Pol II transcription machinery. In transcriptional repression 
by the VDR, such as that of PTH, binding of the VDR-RXR 
complex to a negative VDRE recruits corepressors of the 
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  The VDR protein is modular in nature and like other nuclear 
receptors can be divided into three regions with well-characterized 
functions. The NH2-terminal region contains a ligand-independent 
transactivation function, activation function-1 (AF-1). The central 
region contains the DNA binding domain consisting of two C2-C2 
type zinc fingers, which target the receptor to VDREs. The C-
terminal region contains a multifunctional domain harbouring the 
ligand binding domain (LBD), the RXR heterodimerization motif, 
and a ligand-dependent transactivation function, AF-2. 
  The VDR can modulate the expression of vitD-responsive 
genes in three different ways. (1) The expression of certain genes is 
positively regulated by VDR binding to the VDREs in their pro-
moter regions. These genes include osteocalcin, osteopontin, recep-
tor activator of NF-B ligand (RANKL), and carbonic anhydrase II, 
which are involved in extracellular bone matrix formation and bone 
remodelling. Other genes are the cell adhesion molecule 3 integrin, 
tumor suppressor p21, calbindin-9k, 24-hydroxylase, CYP3A4, 
involucrin, phospholipase C (PLC) 1, and IGF binding protein 
(IGFBP)-3. (2) The expression of other genes is negatively regu-
lated by VDR binding to negative VDREs. The best-described 
genes that are down-regulated by VDR signalling are PTH and 1-
hydroxylase, which are involved in mineral homeostasis. Other 
genes such as those associated with cytokines, IL-2, IL-12, TNF, 
interferon and granulocyte-macrophage colony-stimulating factor, 
and proliferation-associated genes such as those for epidermal 
growth factor receptor, c-myc and K16, are repressed by VDR 
ligands. (3) The expression of some genes is inhibited by antagoniz-
ing the action of certain transcription factors such as nuclear factor 
(NF)-AT and NF-kB. 
  In cancer cells, numerous genes regulated by the VDR have 
been identified by expression microarrays. Many of them are in-
volved in the cell cycle. For example, the VDR induces the expres-
sion of the p21 and p27 genes and plays a role in the arrest of cellu-
lar proliferation and cancer control (see review in [57]). 
  In the cardiovascular system, 1,25-OH-D3 controls the expres-
sion of key genes involved in blood pressure control such as those 
for renin and angiotensin II. VitD analogues also control genes 
involved in the progression of glomerular disease in diabetes. In 
association with an RAS inhibitor, a VDR agonist suppresses the 
induction of fibronectin, TGF- and MCP-1 and reverses the de-
cline of the slit diaphragm proteins nephrin, Neph-1, ZO-1 and 
actinin-4. Combination therapy with an AT1 blocker and a vitD 
analogue markedly ameliorates diabetic nephropathy. VitD plays an 
important role in the immune system. The VDR is present in acti-
vated human mononuclear leukocytes and in B and T lymphocytes. 
In the adaptive immune system, 1,25-dihydroxyvitamin D3 plays an 
immunoregulatory role. Toll-like receptor activation of human 
macrophages up-regulates expression of the VDR and the 
25(OH)D3-1 hydroxylase genes; induction of cathelicidin, an an-
timicrobial peptide, through VDR-mediated gene expression en-
ables intracellular Mycobacterium tuberculosis to be killed. 
  In the endocrine system, besides the parathyroid, vit D acts on 
pancreatic cells; 1,25-OH2-D3 induces insulin secretion, and 
25(OH)D concentration correlates positively with insulin sensitiv-
ity. 
  Because of their antiproliferative effects, Vit D analogues could 
be a major new drug family for cancer treatment (see review in 
[58]). 
  Vitamins A and D are thus good examples of small molecules 
that are more than simple nutritional complements. Vit A plays a 
critical role in organ development and morphogenesis. Vit D and its 
analogues are potentially important drugs with multiple targets - 
cancer, hypertension and cardiovascular diseases – because of its 
pleiotropic effects on gene transcription. We believe that a similar 
picture is emerging for vitamin C. Vits A and D act by specific 
binding to a receptor that is translocated to the nucleus and regu-
lates gene expression. AA seems to act differently. We know of no 
transcriptional factor that binds AA and regulates gene expression. 
Regarding the question of a receptor, the situation is more complex. 
An important question is whether we may consider the transporter 
SVCT2 as a receptor. Regarding its specificity for AA the answer is 
yes, but it is not a nuclear receptor, and regulation of gene expres-
sion by the intracellular concentration of AA is probably not direct. 
CONCLUSION 
  AA has long been studied by groups involved in nutrition and 
has been considered a food supplement. The major biochemical 
function proposed for AA has been its antioxidant property and the 
major cellular function has been to promote extracellular matrix 
formation by stabilising collagen structure.  
  However, although these activities do occur in vivo, recent pro-
gress allows us to consider additional functions, among which 
embryonic/cell differentiation is probably the most promising. It 
will be very interesting to follow the AA distribution in embryos 
and to try to link it to embryonic signalling. The action of AA on 
cell division is probably a good route. We already know that the 
intracellular AA concentration is heterogeneous in adults [59]; 
some tissues have high concentrations, others have much lower 
ones. If the same is true in embryos, we may assume that the 
division rate could be affected by the local AA concentration. As 
the progression and inhibition of cell division are crucial during 
embryogenesis and cell differentiation, we could hypothesize that 
the local AA concentration influences these processes. This 
heterogeneity in AA concentration is probably linked to the 
concentration of the transporter SVCT2 [10], which may act as both 
a transporter and a receptor. The local AA concentration could 
modulate the expression of a battery of genes and influence cell 
division. An alternative mechanism may be direct action of AA on 
the expression of genes involved in mammalian development. 
  Regarding the signalling pathway that could be involved, we 
suggest cAMP pathways (probably through CREB synthesis, as 
seems to be the case for PMP22). As our recent work suggests, AA 
is a competitor of adenylate cyclase activity, suggesting that it is a 
global regulator of the intracellular cAMP pool. Therefore, AA 
could modulate the expression of a battery of genes expressed un-
der the control of cAMP-dependent pathways. Some have already 
been described but a systematic evaluation of genes that could be 
modulated during development will be interesting. 
  A final question concerns the evolution of this mechanism and 
this new property of AA. Could we extrapolate our hypothesis be-
yond mammals? This is a fascinating question and currently there is 
no clear answer. However, we note that the transporter SVCT2 is 
strongly conserved through evolution. Human and Drosophila 
SVCT2s show conservation of about 70% of the coding sequence. 
If this extends to conservation of function, AA may be one of the 
oldest developmental signalling molecules.  
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